Cargando…
Improving Therapeutic Ratios with the Oncotype DX® Ductal Carcinoma In Situ (DCIS) Score
Ductal carcinoma in situ (DCIS) is a non-invasive breast cancer comprising nearly 25% of breast cancer diagnoses in the mammographic era. Current guidelines recommend breast-conserving surgery followed by adjuvant radiotherapy; however, controversy exists regarding the appropriateness of these recom...
Autores principales: | Lalani, Nafisha, Rakovitch, Eileen |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Cureus
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438234/ https://www.ncbi.nlm.nih.gov/pubmed/28534000 http://dx.doi.org/10.7759/cureus.1185 |
Ejemplares similares
-
MiRNA expression deregulation correlates with the Oncotype DX(®) DCIS score
por: Loudig, Olivier, et al.
Publicado: (2022) -
Ductal carcinoma in situ (DCIS)
por: Holland, R
Publicado: (2002) -
Survival results according to Oncotype Dx recurrence score in patients with hormone receptor positive HER-2 negative early-stage breast cancer: first multicenter Oncotype Dx recurrence score survival data of Turkey
por: Ünal, Çağlar, et al.
Publicado: (2023) -
Oncotype DX Recurrence Score in premenopausal women
por: Zhang, Shiliang, et al.
Publicado: (2022) -
Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings
por: Li, Haojia, et al.
Publicado: (2019)